How lending to payers could get your drug to market
This article was originally published in Scrip
Debt financing agreements, often coupled with performance guarantees and added services, could be the way to convince budget-conscious payers to pay out for your expensive drug, according to Soeren Mattke, senior scientist at the Rand Corporation, a research organization that develops public policy solutions.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.